Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database

V. Procházka, T. Papajík, A. Janíková, D. Belada, T. Kozák, D. Šálek, A. Sýkorová, H. Móciková, V. Campr, J. Dlouhá, K. Langová, T. Fürst, M. Trněný,

. 2017 ; 58 (3) : 601-613. [pub] 20160925

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18011011

Grant support
NT12193 MZ0 CEP Register

Optimal frontline treatment in younger high tumor-burden risk follicular lymphoma patients remains a challenge given the reduced efficacy of standard immunochemotherapy (R-CHOP) in widespread disease and unclear role of intensive induction. The retrospective non-randomized pair-matched (1:3) analysis compared 48 intermediate/high Follicular Lymphoma International Prognostic Index (FLIPI) patients receiving intensive rituximab sequential chemotherapy (R-SQ) with 144 random controls (R-CHOP) matched for age, FLIPI score, and maintenance delivery. Complete response rates were 91.7% and 74.1%, respectively (p = .038). After a median follow-up of 8.8 (R-SQ) and 6.5 years (R-CHOP), 5-year time to treatment failure, progression-free survival, and overall survival were 80.9%, 83.2%, and 100% and 57.5%, 60.3%, and 92.1% (p = .0044; p = .0047; p = .22), respectively. Intensive treatment was accompanied by higher acute hematologic toxicity and infections, comparable non-hematologic toxicity, and incidence of secondary malignancies. Intensive induction demonstrates superior long-term disease control compared to R-CHOP, with higher acute hematologic toxicity, but without acute treatment-related mortality. Further studies are needed to define ultra-high-risk FL patients benefiting most from treatment intensity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011011
003      
CZ-PrNML
005      
20191008110725.0
007      
ta
008      
180404s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/10428194.2016.1213834 $2 doi
035    __
$a (PubMed)27666539
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Procházka, Vít $u a Department of Hemato-Oncology, Faculty of Medicine and Dentistry , Palacky University , Olomouc , Czech Republic. $7 xx0143822
245    10
$a Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database / $c V. Procházka, T. Papajík, A. Janíková, D. Belada, T. Kozák, D. Šálek, A. Sýkorová, H. Móciková, V. Campr, J. Dlouhá, K. Langová, T. Fürst, M. Trněný,
520    9_
$a Optimal frontline treatment in younger high tumor-burden risk follicular lymphoma patients remains a challenge given the reduced efficacy of standard immunochemotherapy (R-CHOP) in widespread disease and unclear role of intensive induction. The retrospective non-randomized pair-matched (1:3) analysis compared 48 intermediate/high Follicular Lymphoma International Prognostic Index (FLIPI) patients receiving intensive rituximab sequential chemotherapy (R-SQ) with 144 random controls (R-CHOP) matched for age, FLIPI score, and maintenance delivery. Complete response rates were 91.7% and 74.1%, respectively (p = .038). After a median follow-up of 8.8 (R-SQ) and 6.5 years (R-CHOP), 5-year time to treatment failure, progression-free survival, and overall survival were 80.9%, 83.2%, and 100% and 57.5%, 60.3%, and 92.1% (p = .0044; p = .0047; p = .22), respectively. Intensive treatment was accompanied by higher acute hematologic toxicity and infections, comparable non-hematologic toxicity, and incidence of secondary malignancies. Intensive induction demonstrates superior long-term disease control compared to R-CHOP, with higher acute hematologic toxicity, but without acute treatment-related mortality. Further studies are needed to define ultra-high-risk FL patients benefiting most from treatment intensity.
650    _2
$a dospělí $7 D000328
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a Česká republika $x epidemiologie $7 D018153
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a folikulární lymfom $x diagnóza $x farmakoterapie $x epidemiologie $x mortalita $7 D008224
650    _2
$a udržovací chemoterapie $7 D060046
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a analýza párové shody $7 D016555
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a staging nádorů $7 D009367
650    _2
$a surveillance populace $7 D011159
650    _2
$a indukce remise $7 D012074
650    _2
$a výsledek terapie $7 D016896
650    _2
$a tumor burden $7 D047368
655    _2
$a časopisecké články $7 D016428
700    1_
$a Papajík, Tomáš, $u a Department of Hemato-Oncology, Faculty of Medicine and Dentistry , Palacky University , Olomouc , Czech Republic. $d 1967- $7 xx0060566
700    1_
$a Janíková, Andrea $u b Department of Hematology and Oncology , University Hospital , Brno , Czech Republic. $7 xx0103433
700    1_
$a Belada, David, $u c 4th Department of Internal Medicine - Hematology , University Hospital and Faculty of Medicine , Hradec Kralove , Czech Republic. $d 1972- $7 mzk2006322730
700    1_
$a Kozák, Tomáš $u d Department of Clinical Hematology , University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University , Prague , Czech Republic.
700    1_
$a Šálek, David $u b Department of Hematology and Oncology , University Hospital , Brno , Czech Republic. $7 xx0211647
700    1_
$a Sýkorová, Alice, $u c 4th Department of Internal Medicine - Hematology , University Hospital and Faculty of Medicine , Hradec Kralove , Czech Republic. $d 1975- $7 xx0051467
700    1_
$a Móciková, Heidi, $u d Department of Clinical Hematology , University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University , Prague , Czech Republic. $d 1964- $7 mzk2009517509
700    1_
$a Campr, Vít, $u e Institute of Pathology, University Hospital Motol , Prague , Czech Republic. $d 1960- $7 jo2002148777
700    1_
$a Dlouhá, Jitka $u f Data Management Office, 1st Department of Internal Medicine - Department of Hematology , First Faculty of Medicine and General Teaching Hospital , Prague , Czech Republic.
700    1_
$a Langová, Kateřina $u g Department of Medical Biophysics, Faculty of Medicine and Dentistry , Palacky University , Olomouc , Czech Republic. $7 xx0141371
700    1_
$a Fürst, Tomáš $u h Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science , Palacký University , Olomouc , Czech Republic. $7 mzk2005286891
700    1_
$a Trněný, Marek, $u i 1st Department of Internal Medicine - Department of Hematology , First Faculty of Medicine and General Teaching Hospital , Prague , Czech Republic. $d 1960- $7 nlk20000083659
773    0_
$w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 58, č. 3 (2017), s. 601-613
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27666539 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20191008111141 $b ABA008
999    __
$a ok $b bmc $g 1288496 $s 1007823
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 58 $c 3 $d 601-613 $e 20160925 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
GRA    __
$a NT12193 $p MZ0
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options